“…Since BMS techniques, osteochondral transplantation, and ACI have limitations and shortcomings, such as fibrocartilage regeneration, donor site complications, graft failure, dedifferentiation of seed cells, and two-stage invasive surgical procedures (Fortier et al, 2010;Andriolo et al, 2017;Riboh et al, 2017), MSCs, which are multipotent progenitor cells with an intrinsic potential for multilineage differentiation, self-renewal, low immunogenicity, anti-inflammatory activity, and immunomodulatory effects by suppressing the graft-versushost reaction, may be obtained from multiple tissues of individual patients, and these cells are easily cultured, amplified, and purified (Goldberg et al, 2017;Guadix et al, 2017). MSCs are widely used in cartilage repair and regeneration as seed cells without concerns regarding increasing the risk of cancer (Hernigou et al, 2013;Liu et al, 2018;Han et al, 2019). An increasing number of studies have suggested that peripheral blood (PB) is a potential alternative source of MSCs, which have shown similar chondrogenic differentiation potential with bone marrow-derived MSCs (BM-MSCs) in both in vitro and in vivo studies (Fu et al, 2014a;Wang et al, 2016a).…”